Fig. 3

In vivo combination of MRK-560 with tyrosine kinase inhibition reduces leukemic bone marrow infiltration in a PDX model. a Schematic representation of the experiment. BLI = bioluminescence imaging. b Percentage of hCD45⁺ cells in the blood as assessed by flow cytometry analysis of hCD45-APC after facial vein blood sampling. Left panel depicts evolution; right panel shows analysis at the end of the experiment. Each dot represents a single animal; mean and standard deviation are shown. Data were analyzed by one-way ANOVA; Bonferroni correction for multiple comparisons testing was applied. c Maximum total flux (photons/second) for bioluminescence analysis for all mice. Evolution (left panel) and analysis at the end of the experiment (right panel) are shown. Each dot represents a single animal; mean and standard deviation are shown. Data were analyzed by one-way ANOVA; Bonferroni correction for multiple comparisons testing was applied. Normalized luminescence imaging overlay for all mice at day 7 and day 14 is shown on the right. d Spleen weight and hCD45 staining results for spleen and bone marrow on day 15. Each dot represents an animal; mean and standard deviation are shown. Data were analyzed by one-way ANOVA, and Bonferroni correction for multiple comparisons testing was applied. e Body weight change during treatment for each animal. Mean and standard deviation are shown. f) Quantification of number of goblet cells per millimeter of villus is shown on the left for each animal with mean and standard deviation. g Representative images of PAS staining from mice treated with vehicle, ruxolitinib, MRK-560 or combination for 14 days. Scale bar, 200 µm. ns = not significant (p > 0.05), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001